McKesson Corporation

MCK · NYSE · USD

Can oncology and biopharma services profit growth outrun branded-drug price declines and customer concentration as McKesson separates Medical-Surgical?

Last 4 earnings calls · through Q1 FY2027

Bull case

  • Specialty and oncology platform

    The bull case rests on oncology and multispecialty, where McKesson keeps adding providers and layers services onto distribution so each relationship earns more.

  • Biopharma access services

    Biopharma services add technology revenue on top of distribution, and demand for prior authorization and affordability tools keeps bringing new brands onto the platform.

  • Operating leverage on thin margins

    Because distribution margins are thin, small gains in expense efficiency and generic sourcing fall straight to profit, and management has raised its outlook each quarter.

  • Capital return and share count

    Cash generation funds a shrinking share count and a rising dividend, so profit per share compounds faster than the operating business itself.

Bear case

  • Customer concentration

    The bear case is that a handful of retail and health-system customers generate most of the revenue and can press for better terms as they consolidate.

  • Branded drug price declines

    Branded manufacturers keep cutting list prices and shifting to generics, so reported revenue shrinks and profit has to come from volume and cost instead of price.

  • Medical-Surgical separation

    Separating Medical-Surgical absorbs management attention and balance-sheet capacity while the retained majority stake keeps a slower-growing business in the numbers.

Bull and bear points

Growth & Execution

In short: Oncology and biopharma services grow fast, while prescription technology revenue growth is guided much lower.

Bull · 2

  • Oncology network adds 570 providers in a year

    Provider recruitment brings distribution, group purchasing and practice-management revenue per practice, so the oncology platform grows faster than the underlying drug market.

    Q4 FY2026 call

  • Fiscal 2027 outlook raised above long-term range

    A quarter ago management set fiscal 2027 guidance at 12% to 14% earnings growth; after the first quarter it raised the range and now points to growth above its long-term target.

    Tone shiftQ4 FY2026 → Q1 FY2027
Bear · 2

  • Prescription technology revenue growth guided much lower

    Management cut fiscal 2027 revenue growth guidance for the segment to 2.5% to 6.5%, down from the 9% to 13% guided six months earlier, because third-party logistics revenue swings with product launches.

    Tone shiftQ3 FY2026 → Q4 FY2026

  • Separation keeps a flat-growth segment in the numbers

    Medical-Surgical revenue was $2.8 billion in the latest quarter and the segment is guided to flat to 4% operating profit growth in fiscal 2027 while McKesson prepares it for an IPO.

    Q1 FY2027 call

Profitability & Financial Strength

In short: Margins are thin but improving through expense leverage, while free cash flow is uneven as investment rises.

Bull · 1

  • Operating leverage lifts a thin margin

    Operating margin reached 1.3% in the latest quarter, and operating expenses as a share of gross profit fell 293 basis points for the full year as automation and generic sourcing took cost out.

    Q4 FY2026 call
Bear · 2

  • Cash conversion is thin and uneven

    Free cash flow was $6.4 billion over the last twelve months, 1.6% of revenue, and the first quarter of fiscal 2027 ran negative as working capital and higher capital spending absorbed cash.

    Q1 FY2027 call

  • Separation debt raises interest expense

    Interest expense is guided to $380 million to $420 million in fiscal 2027, up sharply, because the Medical-Surgical separation adds term debt whose proceeds are earmarked for repurchases.

    Q4 FY2026 call

Market Position

In short: Scale makes McKesson a leading distributor, but a few customers and suppliers hold the bargaining power.

Bull · 2

  • Serialized tracking raises the bar for rivals

    Complying with the Drug Supply Chain Security Act took years of investment, and management says a new entrant would have to replicate that capability to participate in pharmaceutical distribution.

    Q2 FY2026 call

  • Branded price cuts mostly hit revenue only

    More than 95% of branded drugs are handled on fee-for-service terms, so manufacturer price cuts and Medicare negotiated prices lower reported revenue without resetting what McKesson earns.

    Q1 FY2027 call
Bear · 2

  • Top ten customers are 73% of revenue

    The largest customer alone is about 24% of consolidated revenue, so contract renewals and any retail bankruptcy or store closure move volume quickly across the whole distribution network.

    10-K, filed 2026-05-08

  • 340B reform could reset customer economics

    The 340B proposal now under comment would change economics for hospitals, contract pharmacies and community providers McKesson serves, and management says it is too early to size the effect.

    Q1 FY2027 call